TrivarX has appointed Dr Danielle Meyrick as CEO and locked in investigational product supply, advancing preparations for its Stabl-Im Phase 1 clinical trial targeting H2 2026.
- Dr Danielle Meyrick appointed CEO with clinical and regulatory expertise
- Contract research organisation Beyond Drug Development engaged for Phase 1 trial
- Investigational product supply secured post-quarter to enable trial start
- Phase 1 trial to assess safety and imaging feasibility in healthy volunteers and oncology
- Cash reserves of $2.44 million support near-term clinical development
Leadership Strengthened to Accelerate Clinical Development
TrivarX (ASX:TRI) has bolstered its executive ranks with the appointment of Dr Danielle Meyrick as CEO, effective 1 June 2026, bringing over 20 years of experience spanning clinical medicine, radiopharmaceutical chemistry, and biotechnology. Her background includes senior roles at Telix Pharmaceuticals, ITM Isotope Technologies Munich, and GenesisCare CRO, equipping her to lead TrivarX’s transition from development to clinical execution of its Stabl-Im stable isotope-enhanced MRI platform.
Since joining, Dr Meyrick has initiated a refreshed development strategy focused on disciplined clinical execution, regulatory engagement, and capital allocation prioritising evidence generation for Stabl-Im. This strategic clarity marks a pivotal shift as TrivarX prepares for its upcoming Phase 1 clinical feasibility study.
Clinical Trial Preparations Advance with CRO Engagement and Product Supply
TrivarX has engaged specialist contract research organisation Beyond Drug Development to drive the Phase 1 clinical trial preparations. Beyond brings expertise in early-phase clinical development, regulatory strategy, and imaging product trials, supporting protocol finalisation, regulatory submissions, and site activation.
The planned Phase 1 study aims to evaluate the safety and tolerability of controlled D2O total body water enrichment in healthy volunteers, alongside characterising enrichment kinetics. An expansion cohort will assess Stabl-Im’s imaging feasibility and preliminary performance in oncology patients, representing a critical step toward broader clinical development.
Crucially, TrivarX secured the investigational product supply necessary to initiate the trial shortly after the quarter ended, removing a significant hurdle for timely commencement. The company is now focused on completing remaining regulatory, ethics, and operational requirements ahead of a targeted H2 2026 trial start.
Financial Position and Strategic Focus
With $2.44 million in cash at the end of June 2026, TrivarX maintains sufficient funding for its near-term clinical activities. The company’s expenditure during the quarter was modest, reflecting a prioritisation of Stabl-Im’s clinical advancement over its mental health-focused technologies, which are currently maintained primarily for intellectual property protection.
TrivarX continues to explore strategic options for its mental health assets, including potential partnerships or licensing, while concentrating capital deployment on activities that will generate meaningful clinical evidence and shareholder value from Stabl-Im.
Market Engagement and Outlook
CEO Dr Meyrick has actively engaged with investors, presenting at the JP Equity Partners ‘Boom of the Biotech II’ event to outline TrivarX’s clinical strategy and commercial potential. This outreach supports broader shareholder engagement as the company approaches key clinical milestones.
Looking ahead, TrivarX plans to finalise its Phase 1 protocol and regulatory documentation, complete formulation and analytical preparations, progress site selection, and establish operational capabilities to support efficient trial execution. The commencement of the Phase 1 clinical program remains contingent on regulatory and operational readiness but is targeted for the second half of 2026.
Bottom Line?
TrivarX’s clinical and operational groundwork for Stabl-Im’s Phase 1 trial is well underway, with leadership and product supply secured, setting a clear path toward clinical validation and value creation.
Questions in the middle?
- Will TrivarX meet its H2 2026 target for Phase 1 trial commencement amid regulatory and operational complexities?
- How might TrivarX’s strategic review reshape the Stabl-Im pipeline or lead to new clinical indications?
- What potential partnerships or licensing deals could emerge for TrivarX’s mental health technologies?